...data YE19 Retrophin Inc. (NASDAQ:RTRX) Fosmetpantotenate Treat pantothenate kinase-associated neurodegeneration (PKAN) Phase III data 3Q19 Revogenex Inc....

...4/29/19 Revance Therapeutics Inc. (NASDAQ:RVNC) DaxibotulinumtoxinA Treat moderate to severe glabellar lines Submit BLA 2Q19 Revogenex Inc....

...metastatic melanoma PDUFA date 6/30/18 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....

...III TACTT3 data Early 2018 Avenue Therapeutics Inc. (NASDAQ:ATXI) / Fortress Biotech Inc. (NASDAQ:FBIO) / Revogenex Inc....

...innovative products and technologies with long-term potential. He highlighted IV tramadol, which Coronado in-licensed from Revogenex Inc....

...which will focus on developing and commercializing products for use in the U.S. hospital market. Revogenex...
...to initiate Phase III trials of the synthetic opioid to treat postoperative pain this year. Revogenex Inc....